ENDO Company Profile

✉ Email this page to a colleague

ENDO has two hundred and thirty-one approved drugs.

There are forty-five US patents protecting ENDO drugs. There is one tentative approval on ENDO drugs.

There are two hundred and seventy-seven patent family members on ENDO drugs in forty-two countries and three hundred and fifty-three supplementary protection certificates in seventeen countries.

International Patents:	277
US Patents:	45
Tradenames:	182
Ingredients:	158
NDAs:	231
Patent Litigation for ENDO:	See patent lawsuits for ENDO
PTAB Cases with ENDO as petitioner:	See PTAB cases with ENDO as petitioner
PTAB Cases with ENDO as patent owner:	See PTAB cases with ENDO as patent owner

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	AMANTADINE HYDROCHLORIDE	amantadine hydrochloride	SYRUP;ORAL	077992-001	Dec 12, 2006		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Endo Operations	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205784-004	Jun 9, 2017		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Endo Operations	VASOSTRICT	vasopressin	SOLUTION;INTRAVENOUS	204485-001	Apr 17, 2014	AP	RX	Yes	Yes	9,744,209	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-006	Dec 9, 2011	8,114,383	⤷ Subscribe
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-003	Dec 9, 2011	8,309,060	⤷ Subscribe
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	8,267,903	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	Injection	20 units/mL, 1 mL	➤ Subscribe	2018-03-23
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-05-29
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2011-03-09
➤ Subscribe	Nasal Spray	500 mcg/spray	➤ Subscribe	2017-04-28
➤ Subscribe	Gel	1%	➤ Subscribe	2008-08-21
➤ Subscribe	Injection	1 mg/mL, 50 mL vials	➤ Subscribe	2011-12-16
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Injection	1 mg/mL ampules	➤ Subscribe	2016-03-09
➤ Subscribe	Extended-release Tablets	5 mg, 10 mg, 20 mg and 40 mg	➤ Subscribe	2007-11-23
➤ Subscribe	Extended-release Tablets	30 mg	➤ Subscribe	2008-06-12
➤ Subscribe	Gel	10 mg/actuation	➤ Subscribe	2012-08-14
➤ Subscribe	Injection	100 mg/mL, 2.5 mL vials	➤ Subscribe	2007-09-24
➤ Subscribe	Injection	250 mg/mL	➤ Subscribe	2014-06-11

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1315485	2015C/048	Belgium	⤷ Subscribe	PRODUCT NAME: LUBIPROSTONE; AUTHORISATION NUMBER AND DATE: PL21341/0003 20150317
0388054	21/2005	Austria	⤷ Subscribe	PRODUCT NAME: DARIFENACIN ODER EIN PHARMAZEUTISCH ANNEHEMBARES SALZ HIEVON; REGISTRATION NO/DATE: EU/1/04/294/001 - EU/1/04/294/012 20041022
2330892	1690060-7	Sweden	⤷ Subscribe	PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REG. NO/DATE: EU/1/15/1062 20151201
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.